Jackson Creek Investment Advisors LLC Sells 244 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Jackson Creek Investment Advisors LLC decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,052 shares of the company’s stock after selling 244 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Krystal Biotech were worth $1,261,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in KRYS. State Street Corp raised its position in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares in the last quarter. Geode Capital Management LLC raised its position in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares during the period. Franklin Resources Inc. raised its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company’s stock worth $38,095,000 after purchasing an additional 2,954 shares during the period. Finally, Braidwell LP increased its position in shares of Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KRYS. Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday. They set a “buy” rating and a $245.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $179.93 on Friday. The firm’s 50 day simple moving average is $161.18 and its 200-day simple moving average is $174.74. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The firm has a market cap of $5.18 billion, a PE ratio of 60.18 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the business posted $0.30 EPS. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. Equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).